Lamisil cream

Lamisil is a globally recognized antifungal medication, primarily known for its effectiveness in treating skin infections such as athlete's foot and ringworm. The brand was originally developed by the Swiss pharmaceutical giant Novartis AG in the late 1980s, introducing the active ingredient terbinafine hydrochloride to the market. Over the decades, it became a staple in both prescription and over-the-counter (OTC) foot health categories.

In a significant shift in ownership, the brand's OTC rights were divested by Haleon (a consumer healthcare spin-off from GSK and Pfizer) in late 2023. The brand was acquired by Karo Healthcare, a Swedish-based company specializing in consumer healthcare products. Today, Lamisil is the flagship brand in Karo's portfolio.

Manufacturing of Lamisil occurs in various locations globally to meet local market demands. Major production hubs have historically included facilities in Switzerland and the United States. While the brand is now owned by Karo Healthcare, the physical manufacturing often involves a network of established pharmaceutical partners and contract manufacturers across Europe and North America.